Be alerted to new data & content
Be the first to see:
✔ The latest product updates
✔ Receive relevant supportive materials and resources
About KEYTRUDA® (pembrolizumab) in melanoma
KEYTRUDA® (PEMBROLIZUMAB) IN MELANOMA
Bringing immunotherapy to Stage IIB-IV melanoma
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Resected
Stage IIB & IIC
melanoma
KEYTRUDA can be used in the adjuvant treatment of Stage IIB and IIC melanoma after complete resection
Resected
Stage III melanoma
KEYTRUDA can be used in the adjuvant treatment of Stage III melanoma after complete resection
Find out more about KEYTRUDA in Stage III melanoma
Advanced
melanoma
KEYTRUDA can be used in the treatment of advanced (unresectable or metastatic) melanoma
Find out more about KEYTRUDA in advanced melanoma (coming soon)
Licensed indications1
KEYTRUDA as monotherapy is indicated for:
- The treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma
- The adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection
Dosing and administration
Adult patients
200 mg
every three weeks
400 mg
every six weeks
Paediatric patients
2 mg/kg bw
every three weeks, up to a maximum of 200 mg
30 minute
IV infusion time
For adjuvant treatment, patients should receive KEYTRUDA until disease recurrence, unacceptable toxicity or up to one year. For advanced melanoma, patients should receive KEYTRUDA until disease recurrence or unacceptable toxicity. Please refer to the SmPC before prescribing.
Training and resources
Reference
- KEYTRUDA Summary of Product Characteristics.
Abbreviation
IV = Intravenous
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
